Christopher Chai
Fortune : 51 994 $ au 31/07/2026
Fortune : 51 994 $ au 31/07/2026
Christopher Y.
Chai is currently an Independent Director at Surrozen, Inc. since 2021, a Director at Surrozen Operating, Inc. since 2021, a Venture Partner at GSK Equity Investments Ltd. since 2021, and a Venture Partner at SR One Capital Management LP since 2021.
Former roles include Director at Transcriptx, Inc. from 2016 to 2020, Chief Financial & Accounting Officer at Principia Biopharma, Inc. from 2013 to 2020, Treasurer, VP & Head-Investor Relations at CV Therapeutics, Inc. in 2006, CFO, Senior VP & Investor Relations Contact at MAP Pharmaceuticals LLC from 2011 to 2013, and Principal at JPMorgan Chase & Co. Education includes undergraduate studies at Cornell University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SURROZEN INC 0,02% | 13/05/2026 | 2 341 ( 0,02% ) | 51 994 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| SURROZEN, INC. | Directeur/Membre du Conseil | 01/04/2021 |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Private Equity Investor | 11/02/2021 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Directeur/Membre du Conseil | 06/05/2021 |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Private Equity Investor | 01/01/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
| PRINCIPIA BIOPHARMA INC. | Directeur Financier/CFO | 28/09/2020 |
Transcriptx, Inc.
Transcriptx, Inc. BiotechnologyHealth Technology Develops mRNA therapies intended to treat primary ciliary dyskinesia | Directeur/Membre du Conseil | 01/01/2020 |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Directeur Financier/CFO | 01/01/2013 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule drugs | Public Communications Contact | 01/01/2006 |
| JPMORGAN CHASE & CO. | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 10 |
|---|---|
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule drugs | Health Technology |
JPMorgan Chase & Co.
JPMorgan Chase & Co. Major BanksFinance Provides banking, asset management, investment banking, credit card and mortgage services | Finance |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Health Technology |
Principia Biopharma, Inc.
Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a R&D driven and AI-powered biopharma company | Health Technology |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Finance |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Health Technology |
Transcriptx, Inc.
Transcriptx, Inc. BiotechnologyHealth Technology Develops mRNA therapies intended to treat primary ciliary dyskinesia | Health Technology |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Finance |
Surrozen, Inc.
Surrozen, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovering and developing drug candidates | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national